{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:52:16Z","timestamp":1791388336100,"version":"4.3.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehag730","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:16:39Z","timestamp":1788156999000},"source":"Crossref","is-referenced-by-count":0,"title":["Using gap-to-goal to guide treatment escalation: lessons from VICTORION-Challenge and beyond"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3832-0734","authenticated-orcid":false,"given":"Irene","family":"Karungi","sequence":"first","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health, Imperial College London , School of Public Health Building, 90 Wood Lane, London W12 0BZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health, Imperial College London , School of Public Health Building, 90 Wood Lane, London W12 0BZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026100711014621800_ehag730-B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026100711014621800_ehag730-B2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2012","journal-title":"Lancet"},{"key":"2026100711014621800_ehag730-B3","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026100711014621800_ehag730-B4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026100711014621800_ehag730-B5","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/eurjpc\/zwaa156","article-title":"Current perceptions and practices in lipid management: results of a European Society of Cardiology\/European Atherosclerosis Society survey","volume":"28","author":"Koskinas","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026100711014621800_ehag730-B6","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1093\/eurheartj\/ehaf685","article-title":"Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial","volume":"47","author":"Landmesser","year":"2026","journal-title":"Eur Heart J"},{"key":"2026100711014621800_ehag730-B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag738","article-title":"Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial","author":"Hilgendorf","year":"2026","journal-title":"Eur Heart J"},{"key":"2026100711014621800_ehag730-B8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100711014621800_ehag730-B9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100711014621800_ehag730-B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1161\/CIRCULATIONAHA.125.075388","article-title":"Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS randomized clinical trial","volume":"153","author":"Raposeiras-Roub\u00edn","year":"2026","journal-title":"Circulation"},{"key":"2026100711014621800_ehag730-B11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2026100711014621800_ehag730-B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100711014621800_ehag730-B13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jacc.2026.03.036","article-title":"Oral PCSK9 inhibitor enlicitide versus oral nonstatin therapies: a phase 3 randomized clinical trial","volume":"88","author":"Catapano","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026100711014621800_ehag730-B14"},{"key":"2026100711014621800_ehag730-B15","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag730\/70825863\/ehag730.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag730\/70825863\/ehag730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag730\/70825863\/ehag730.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:01:52Z","timestamp":1791385312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag730\/8772191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag730","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"ehag730"}}